Last reviewed · How we verify
METHYLPREDNISOLONE — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
METHYLPREDNISOLONE (METHYLPREDNISOLONE). Bupivacaine blocks nerve impulses by increasing the threshold for electrical excitation, slowing propagation, and reducing the rate of rise of the action potential.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| METHYLPREDNISOLONE TARGET | METHYLPREDNISOLONE | marketed | 1957-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- METHYLPREDNISOLONE CI watch — RSS
- METHYLPREDNISOLONE CI watch — Atom
- METHYLPREDNISOLONE CI watch — JSON
- METHYLPREDNISOLONE alone — RSS
Cite this brief
Drug Landscape (2026). METHYLPREDNISOLONE — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl650. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing